These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions. Yañez MJ; Marín T; Balboa E; Klein AD; Alvarez AR; Zanlungo S Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165875. PubMed ID: 32522631 [TBL] [Abstract][Full Text] [Related]
66. Lysosomal storage disorders in the newborn. Staretz-Chacham O; Lang TC; LaMarca ME; Krasnewich D; Sidransky E Pediatrics; 2009 Apr; 123(4):1191-207. PubMed ID: 19336380 [TBL] [Abstract][Full Text] [Related]
67. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. vom Dahl S; Mengel E Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):619-28. PubMed ID: 20955964 [TBL] [Abstract][Full Text] [Related]
68. Pulmonary Involvement in Niemann-Pick Disease: A State-of-the-Art Review. von Ranke FM; Pereira Freitas HM; Mançano AD; Rodrigues RS; Hochhegger B; Escuissato D; Araujo Neto CA; da Silva TK; Marchiori E Lung; 2016 Aug; 194(4):511-8. PubMed ID: 27164983 [TBL] [Abstract][Full Text] [Related]
69. An update on multiplexed mass spectrometry-based lysosomal storage disease diagnosis. Darie-Ion L; Petre BA Mass Spectrom Rev; 2024; 43(5):1135-1149. PubMed ID: 37584312 [TBL] [Abstract][Full Text] [Related]
70. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). McGovern MM; Avetisyan R; Sanson BJ; Lidove O Orphanet J Rare Dis; 2017 Feb; 12(1):41. PubMed ID: 28228103 [TBL] [Abstract][Full Text] [Related]
73. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Aerts JM; van Breemen MJ; Bussink AP; Ghauharali K; Sprenger R; Boot RG; Groener JE; Hollak CE; Maas M; Smit S; Hoefsloot HC; Smilde AK; Vissers JP; de Jong S; Speijer D; de Koster CG Acta Paediatr; 2008 Apr; 97(457):7-14. PubMed ID: 18339181 [TBL] [Abstract][Full Text] [Related]
74. Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective. Pinto C; Sousa D; Ghilas V; Dardis A; Scarpa M; Macedo MF Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884674 [TBL] [Abstract][Full Text] [Related]
75. Expanded newborn screening by mass spectrometry: New tests, future perspectives. Ombrone D; Giocaliere E; Forni G; Malvagia S; la Marca G Mass Spectrom Rev; 2016; 35(1):71-84. PubMed ID: 25952022 [TBL] [Abstract][Full Text] [Related]
76. Newborn screening for lysosomal storage diseases. Gelb MH; Scott CR; Turecek F Clin Chem; 2015 Feb; 61(2):335-46. PubMed ID: 25477536 [TBL] [Abstract][Full Text] [Related]
77. Application of mass spectrometry in newborn screening: about both small molecular diseases and lysosomal storage diseases. Hwu WL; Chien YH; Lee NC; Wang SF; Chiang SC; Hsu LW Top Curr Chem; 2014; 336():177-96. PubMed ID: 22911488 [TBL] [Abstract][Full Text] [Related]
78. Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies. Stepien KM; Cufflin N; Donald A; Jones S; Church H; Hargreaves IP Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142486 [TBL] [Abstract][Full Text] [Related]
79. The Liver and Lysosomal Storage Diseases: From Pathophysiology to Clinical Presentation, Diagnostics, and Treatment. Lipiński P; Tylki-Szymańska A Diagnostics (Basel); 2024 Jun; 14(12):. PubMed ID: 38928715 [TBL] [Abstract][Full Text] [Related]
80. [How does the landscape change in lysosomal storage disease]. Parini R Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]